Johnson & Johnson $JNJ Holdings Raised by Exchange Traded Concepts LLC

Key Points

• Exchange Traded Concepts LLC increased its stake in Johnson & Johnson by 104.2% in the second quarter, owning 173,966 shares valued at approximately $26.57 million.
• Insider selling was noted as EVP Jennifer L. Taubert sold 56,471 shares for over $10 million, reducing her holdings by 24.08%.
• Johnson & Johnson reported earnings of $2.77 per share for the last quarter, surpassing expectations with revenue of $23.74 billion.

Exchange Traded Concepts LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 104.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 173,966 shares of the company's stock after purchasing an additional 88,777 shares during the period. Exchange Traded Concepts LLC's holdings in Johnson & Johnson were worth $26,573,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in JNJ. Brighton Jones LLC boosted its holdings in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after purchasing an additional 6,332 shares in the last quarter. Hudson Value Partners LLC boosted its holdings in Johnson & Johnson by 2.5% in the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock valued at $5,648,000 after purchasing an additional 1,022 shares in the last quarter. Two Sigma Investments LP acquired a new position in Johnson & Johnson in the fourth quarter valued at approximately $9,222,000. First Heartland Consultants Inc. acquired a new position in Johnson & Johnson in the fourth quarter valued at approximately $1,269,000. Finally, 49 Wealth Management LLC acquired a new position in Johnson & Johnson in the fourth quarter valued at approximately $211,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Trading Up 1.0%

NYSE:JNJ traded up $1.81 during mid-day trading on Friday, reaching $175.97. The company's stock had a trading volume of 25,617,065 shares, compared to its average volume of 6,995,150. The company's fifty day simple moving average is $172.80 and its two-hundred day simple moving average is $161.69. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $181.16. The stock has a market cap of $423.80 billion, a P/E ratio of 18.82, a P/E/G ratio of 2.22 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company's revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the company posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 3.0%. Johnson & Johnson's payout ratio is currently 55.61%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Citigroup increased their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a report on Thursday, August 21st. Royal Bank Of Canada increased their price target on Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. UBS Group increased their price target on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a report on Thursday, July 17th. Finally, JPMorgan Chase & Co. increased their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the stock a "neutral" rating in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $177.87.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.